A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 956-969

  Zhang, Hongzheng ^a   Yun, Sujin ^a   Batuwangala, Thil D ^b   Steward, Michael ^b   Holmes, Steve D ^b   Pan, Lin ^c   Tighiouart, Mourad ^c   Shin, Hyung Ju C ^d   Koenig, Lydia ^a   Park, Wungki ^a   Rycroft, Daniel ^b   Nannapaneni, Sreenivas ^a   Wang, Yuxiang ^a   Chen, Zhuo ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Domantis Limited   (United Kingdom)

^c EMORY UNIVERSITY   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

bevacizumab; cetuximab; dual targeting antibody; EGFR; head and neck cancer; lung cancer; VEGF

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DUAL TARGETING IMMUNOGLOBULIN G ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ONCOGENE K RAS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOGLOBULIN G; LUNG NEOPLASMS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862586383     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26427     Document Type: Article

References (52)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N,. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Tabernero J,. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203-20. (Pubitemid 46569773)
3. Ellis LM,. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004; 18: 1007-21, viii. (Pubitemid 39335756)
4. Ellis LM, Rosen L, Gordon MS,. Overview of anti-VEGF therapy and angiogenesis. I. Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 2006; 4 (Suppl 1-10):quz 1-2.
5. Verheul HM, Pinedo HM,. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85. (Pubitemid 46809172)
6. Hsu JY, Wakelee HA,. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009; 23: 289-304.
7. Chen HX, Cleck JN,. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
8. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
9. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72.
10. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Rosello S, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28: 1181-9.
11. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-9.
12. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-75.
13. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-57.
14. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011; 121: 1313-28.
15. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-80.
16. Tappenden P, Jones R, Paisley S, Carroll C,. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007; 11: 1-128, iii-iv.
17. Fojo T, Grady C,. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-8.
18. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM,. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21: 484-90. (Pubitemid 37324200)
19. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G,. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323: 1610-4.
20. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, Yang CS, Chen ZG, Shin DM,. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 2008; 123: 1005-14.
21. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY,. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96: 1769-80. (Pubitemid 39654571)
22. Durocher Y, Perret S, Kamen A,. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30: E9.
23. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J,. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9. (Pubitemid 24058195)
24. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR, Fidler IJ,. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65: 3716-25. (Pubitemid 40616349)
25. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A,. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006; 6: 295.
26. Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G, et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006; 208: 344-53. (Pubitemid 43993425)
27. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27. (Pubitemid 46202320)
28. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68. (Pubitemid 39506617)
29. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J,. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-86.
30. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB,. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exper Ther 1999; 288: 371-8. (Pubitemid 29113511)
31. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 2005; 56: 455-64. (Pubitemid 41549146)
32. Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 2007; 104: 12468-73. (Pubitemid 47206161)
33. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL,. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-6.
34. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H,. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-9. (Pubitemid 41430564)
35. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O,. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-8.
36. Sathyan KM, Nalinakumari KR, Kannan S,. H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma. Mod Pathol 2007; 20: 1141-8. (Pubitemid 47609061)
37. Rini BI,. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13: 1098-106. (Pubitemid 46424048)
38. Gordon MS, Cunningham D,. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69 (Suppl 3): 25-33. (Pubitemid 41680950)
39. Gressett SM, Shah SR,. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43: 490-501.
40. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478-83. (Pubitemid 46364184)
41. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN,. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-9. (Pubitemid 47242797)
42. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA,. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7: 2288-97.
43. Jain RK,. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814s-9s.
44. Minchinton AI, Tannock IF,. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92. (Pubitemid 44140857)
45. Li KC, Pandit SD, Guccione S, Bednarski MD,. Molecular imaging applications in nanomedicine. Biomed Microdevices 2004; 6: 113-6. (Pubitemid 38801851)
46. Lucio-Eterovic AK, Piao Y, de Groot JF,. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589-99.
47. Dowlati A,. Hunting and trapping the vascular endothelial growth factor. J Clin Oncol 2010; 28: 185-7.
48. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
49. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24. (Pubitemid 46089672)
50. Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F,. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009; 14: 378-90.
51. Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E, Akkerman JW, Pili R, Voest EE,. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13: 5341-7. (Pubitemid 47510358)
52. Gonzalez-Angulo AM, Hortobagyi GN, Ellis LM,. Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 2011; 8: 319-20.